RCKT$2.443.94%-0.10
After Hours: 2.40-0.04 -1.64%
Rocket Pharmaceuticals Inc (RCKT)
Date: 2026-10-30 16:00O: 2.50H: 2.57L: 2.37C: 2.44Vol: 1.535M
Rocket Pharmaceuticals Inc stock is traded at $2.44, with a volume of 1,535,033. It is down -3.94% in the last 24 hours and down -7.22% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Previous Close:
$2.54
Open:
$2.50
24h Volume:
1,535,033
Relative Volume:
0.86
Market Cap:
$267.85M
Revenue:
-
Net Income/Loss:
-$209.38M
P/E Ratio:
-
EPS:
-$1.88
Net Cash Flow:
-$179.81M
1W Performance:
+6.55%
1M Performance:
-7.22%
6M Performance:
-29.89%
1Y Performance:
-34.05%
1-Day Range:
$2.37$2.57
1-Week Range:
$2.22$2.67
52-Week Range:
$2.17$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
646-440-9100Address
350 FIFTH AVENUE, NEW YORK, NY, USACompare RCKT vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT Rocket Pharmaceuticals Inc | $2.44 | $267.85M | $0 | -$209.38M | -$179.81M | -$1.88 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Chart is being upgraded
This chart will be back soon.
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
- Militello JohnSep 15 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $3.30
- #Shares
- 6,897
- Value ($)
- 22,730
- #Shares Total
- 0
- Militello JohnSep 14 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $3.32
- #Shares
- 6,857
- Value ($)
- 22,731
- #Shares Total
- 0
- Wilson MartinSep 11 '26Officer
- Transaction
- Proposed Sale
- Cost
- $3.40
- #Shares
- 75,364
- Value ($)
- 256,486
- #Shares Total
- 0
- Militello JohnSep 11 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $3.40
- #Shares
- 8,923
- Value ($)
- 30,368
- #Shares Total
- 0
- Wilson MartinAug 18 '26Officer
- Transaction
- Proposed Sale
- Cost
- $3.38
- #Shares
- 631
- Value ($)
- 2,134
- #Shares Total
- 0
- Militello JohnAug 18 '26Former Officer
- Transaction
- Proposed Sale
- Cost
- $3.38
- #Shares
- 1,252
- Value ($)
- 4,234
- #Shares Total
- 0
- Wilson MartinAug 18 '26General Counsel
- Transaction
- Sale
- Cost
- $3.38
- #Shares
- 631
- Value ($)
- 2,133
- #Shares Total
- 673,853
- Shah GauravAug 18 '26CEO
- Transaction
- Sale
- Cost
- $3.38
- #Shares
- 2,293
- Value ($)
- 7,753
- #Shares Total
- 1,056,594
- Shah GauravAug 18 '26Officer
- Transaction
- Proposed Sale
- Cost
- $3.38
- #Shares
- 2,293
- Value ($)
- 7,754
- #Shares Total
- 0
- Shah GauravAug 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $3.38
- #Shares
- 2,837
- Value ($)
- 9,592
- #Shares Total
- 0
